Ractigen Therapeutics Doses First Patient in Phase I Trial for RAG-17 in SOD1-ALS
December 27, 2024
Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing RNA-based innovative therapies, announced the successful dosing of the first patient in the Phase I clinical